Novo Nordisk stock news
On October 12, 2026, Novo Nordisk entered into an exclusive out--licensing agreement valued at up to $2.6 billion with Hengrui Pharmaceuticals for HRS--1596, an investigational oral dual GLP--1/GIP receptor agonist being developed for obesity and type 2 diabetes. Under the terms of the deal, Novo Nordisk secures exclusive rights to develop, manufacture, and commercialize HRS--1596 globally, excluding mainland China, Hong Kong, Macau, and Taiwan. The structure of the transaction includes an upfront payment of $300 million to Hengrui, with up to $2.3 billion in contingent development, regulatory, and commercial milestone payments, as well as tiered sales royalties. The transaction is expected to close in the fourth quarter of 2026.